Retatrutide, developed by Soma, represents a exciting advance in weight regulation. This unique drug combines incretin receptor agonist activity with GIP pathway activation , indicating substantial potential in trial findings for weight improvement. Researchers believe this treatment is expected to provide a different pathway for individuals strugg